News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Diabetes, Infectious Diseases Early Focus of San Antonio Biomed Plan

David Holley, Xconomy Texas —  San Antonio — [Updated 12/14/17, 11:54 p.m. See below.] ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
CTRC patients enrolled in GenSpera cancer drug trial San Antonio Business Journal
March 28, 2011

The Cancer Therapy & Research Center has enrolled its first patient in a Phase 1 clinical trial using GenSpera's new G-202 chemotherapeutic agent.

Cancer drug company GenSpera Inc. said Monday that the first patient received a dosage of the company's experimental drug, G-202, at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio.

San Antonio-based GenSpera (OTCBB: GNSZ) is conducting Phase 1 clinical trials at the University of Wisconsin Carbone Cancer Center and now the CTRC.

 

Stay informed. Subscribe to BioMed SA news alerts.